# Development of Standards for Cation Exchange Chromatography Column Qualification

Jie (Amy) Liu, Hua Wang, Huiping Tu, Diane McCarthy and Fouad Atouf Global Biologics, United States Pharmacopeia, Rockville, Maryland, USA

## Introduction

Standards for qualification of chromatographic columns were identified as a high priority during USP-sponsored roundtables with stakeholders to identify challenges in biologics development that could be alleviated with standards. Cation Exchange Chromatography (CEX) analysis is commonly used to characterize the charge heterogeneity of therapeutic proteins by determining acidic and basic charge variants. Salt gradient and pH gradient are two widely used methods of CEX analysis. The aims of this proof-ofconcept study were to establish both pH gradient and salt gradient CEX methods and utilize them to evaluate three USP monoclonal antibody standards in development (USP mAb001, USP mAb002 & USP mAb003) on columns from three different vendors. Resulting profiles and peak resolution were evaluated to select a candidate for further development as a standard for CEX column qualification.

## Materials and Methods

#### **Materials:**

Table 1: USP mAbs for CEX column qualification


Table 1. Col 111/100 for OLA Coldinii qualification								
#	Name	Subclass	pl*	Formulation Buffer				
1	USP mAb001	lgG1	~9.3	9.0 mg/mL sodium chloride, 7.35 mg/mL sodium citrate dihydrate, 0.7 mg/mL polysorbate 80, pH 6.5				
2	USP mAb002	lgG1	~7.8	0.58% Monobasic sodium phosphate monohydrate, 0.12% Dibasic sodium phosphate anhydrous, 6% $\alpha$ , $\alpha$ -trehalose dehydrate, 0.04% Polysorbate 20, pH 6.2				
3	USP mAb003	lgG1	~7.8	20 mM Histidine HCI, 120 mM Sucrose, 0.02% Polysorbate 20, pH 6.0				

<sup>\*</sup> pl value from in-house cIEF data

**Table 2**: Columns used for evaluation of USP mAbs for CEX column qualification standards

	Column 1	Column 2	Column 3		
Column Name	BioResolve SCX mAb	BioPro SF	BioMab NP5		
Column Vendor	Water	Agilent	YMC		
Column Type	SCX	SCX	WCX		
Particle morphology	Non porous	Non porous	Non porous		
Matrix	Hydrophilic polymer	Hydrophilic polymer	Hydrophilic polymer		
Particle size (µm)	3	5	5		
Functional group ligand	Sulfonic acid (SO3-)	Sulfonic acid (SO3-)	СООН		
Denmension	4.6 x 100 mm	4.6 x 100 mm	4.6 x 250 mm		
Column Material	Stainless steel	PEEK	PEEK		

#### Methods:





**Figure 1.** Workflow for evaluation of USP mAbs for CEX column qualification standards

Table 3: HPLC conditions by pH gradient and salt gradient methods

Table 3: HPLC conditions by pH gradient and salt gradient methods								
<b>HPLC Conditions</b>	pH Gradient Method	Salt Gradient Method						
Mobile Phase A	BioResolve CX pH Buffer A (pH 5.2 -6.0)	20 mM phosphate, pH 6.7; 20 mM MES, pH 6.1; 20 mM MES, pH 6.7						
Mobile Phase B	BioResolve CX pH Buffer B (pH 9.5 -10.2)	20 mM phosphate, pH 6.7 + 0.5 M NaCl; 20 mM MES, pH 6.1 + 0.5 M NaCl; 20 mM MES, pH 6.7 + 0.5 M NaCl						
Salt Gradient Slope	0.219 pH unit/min	15-115 mM or 50-115 mM NaCl over 30 min						
Detection (UV)		280 nm						
Loading Amount (µg)		~30						

## Results








Figure 2. Profiles of USP mAb001 (A), USP mAb002 (B) and USP mAb003 (C) on different columns by pH gradient method


**Table 4:** Reproducibility and relative percentage of charge variants by pH gradient method

USP mAb002 (n=3)

	% acidic peak	% main peak	% basic peak	% acidic peak	% main peak	% basic peak	% acidic peak	% main peak	% basio
Column 1 (SCX)	17.2 (3.2)	62.1 (0.2)	20.6 (3.2)	23.9 (2.7)	70.7 (0.5)	5.4 (5.9)	22.5 (0.6)	59.3 (0.3)	18.2 (0
Column 2 (SCX)	15.1 (1.8)	63.8 (0.4)	21.1 (0.9)	19.0 (1.1)	74.6 (0.1)	6.3 (2.8)	22.6 (0.4)	58.6 (0.4)	18.8 (1
Column 3 (WCX)	18.3 (3.9)	60.9 (0.8)	20.8 (1.1)	18.0 (0.9)	73.7 (0.1)	8.3 (1.4)	22.8 <sup>b</sup> (2.9)	61.2 (0.1)	16.0 <sup>b</sup> (3

## Results – cont'd

#### Part II: by Salt Gradient Method



**Figure 3.** Profiles of USP mAb001 (A), USP mAb002 (B) and USP mAb003 (C) on different columns by salt gradient method

**Table 5:** Reproducibility and relative percentage of charge variants by salt gradient methods

	USF	9 mAb001 (ı	n=3)	USP mAb002 (n=3)			USP mAb003a (n=3)		
	% acidic peak	% main peak	% basic peak	% acidic peak	% main peak	% basic peak	% acidic peak	% main peak	% basic peak
Column 2 (SCX)	22.5 (0.1)	52.3 (0.2)	25.0 (0.5)	25.2 (0.1)	69.3 (0.1)	5.2 (1.6)	26.2 (0.5)	53.9 (0.3)	20.0 (0.3)
Column 1 (SCX)	22.5 (3.2)	59.1 (1.1)	19.2 (0.3)	27.9 (0.6)	67.9 (0.3)	4.2 (0.7)	26.2 (0.9)	54.0 (0.3)	19.8 (0.5)
Column 3 (WCX)	22.2 (0.2)	55.6 (0.2)	22.2 (0.5)	22.8 (0.6)	73.4 (0.2)	3.8 (1.1)	24.5 (1.1)	56.1 (0.3)	19.4 (0.7)
Data are shown as mean of n =3 and CV% in brackets  a Peak fronting was observed									

# Conclusions

USP mAb001 (n=3)

- Generic pH gradient and salt gradient CEX methods were established and used to evaluate the charge variant profiles for three USP mAbs on columns from 3 different vendors, including two SCX columns and one WCX column
  - Better resolution of charge variants on SCX columns was observed, suggesting further optimization may be needed for CEX columns
  - Peak fronting was observed for USP mAb003 on all three columns
- The percentages of Main, Acidic and Basic peaks were similar across columns for each mAb
- USP mAb001 was selected as the top candidate for further development. This mAb was prioritized because:

USP mAb003a (n=3)

- Four acidic and multiple basic charge variants could be resolved by both pH gradient and salt gradient CEX chromatography
- It yielded a consistent charge variant profile across the 3 columns tested
- Next steps include identification of individual peaks and testing on additional columns

#### Note: USP mAbs standards will be released in Spring/Summer 2020

### References

 Qi Wang, et al. (2019) Development of pH Gradient Mobile Phase Concentrates for Robust, High Resolution mAb Charge Variant Analysis (Waters application note).
 David A. Michels, et al. (2015) Separation Methods and Orthogonal Techniques: State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. 237-284.

#### Disclaimer

Certain commercial equipment, instruments, vendors, or materials may be identified in this poster to specify adequately the experimental procedure. Such identification does not imply approval, endorsement, or certification by USP of a particular brand or product, nor does it imply that the equipment, instrument, vendor, or material is necessarily the best available for the purpose or that any other brand or product was judged to be unsatisfactory or inadequate. All product names, logos, and brands are property of their respective owners.